07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Bio3 Research, Protelica deal

Bio3 exercised an option to license exclusive rights to the preclinical high mobility group box 1 (HMGB1) antagonists that the companies were co-developing under a 2008 deal to treat cardiovascular diseases, including arterial stenosis, restenosis...
07:00 , Apr 15, 2010 |  BC Innovations  |  Targets & Mechanisms

Inhibiting inflammation in epilepsy

A team of Italian and Dutch academics has identified two proinflammatory targets in the brain- toll-like receptor 4 (TLR4) and high mobility group box 1 ( HMGB1 )-that help drive epileptic seizures in mice. 1...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy High mobility group box 1 (HMGB1); toll-like receptor 4 (TLR4) Studies in human tissue and in mice suggest that antagonizing HMGB1 or its receptor...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

Bio3 Research, ProtElix Inc. deal

ProtElix received non-exclusive, worldwide rights to Bio3's IP covering high mobility group B1 ( HMGB1 ), a pro-inflammatory cytokine, for cardiovascular disorders. ProtElix will use its antibody mimics platform to develop mimic-Abs against the target...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Clinical News

Biocysan: Phase III start

Next month, the partners will begin a Mexican Phase III trial of oral Biocysan in 100 patients. Daxley licensed Latin American rights to Biocysan from Bio3. Bio3 Research s.r.l. , Milan, Italy   Daxley Group...
08:00 , Dec 12, 2005 |  BC Week In Review  |  Company News

Bio3 Research, Cephalon, Creabilis Therapeutics deal

CEPH received an exclusive option to develop and commercialize K252a, a preclinical kinase inhibitor to treat psoriasis and restenosis. The compound is being developed by Creabilis and Bio3. Bio3 Research s.r.l. , Milan, Italy  ...